Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06029439 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Assess the Safety and Effectiveness of NMRA-335140-501

StatusTerminated
PhasePhase 3
Started2023-11-10
View on ClinicalTrials.gov ↗
Why the trial stopped
NMRA-335140 did not achieve the primary endpoint across three randomized controlled trials. Program discontinued due to lack of efficacy in MDD.
This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy and safety of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), and complete the 6 weeks double-blind treatment, provide informed consent, and meet eligibility criteria, may enter this extension study.

Amendment history 3 changes detected by DataLookout

2026-09-15
Trial terminated: NMRA-335140 did not achieve the primary endpoint across three randomized controlled trials. Program discontinued due to...
2026-09-15
Primary completion confirmed: August 2026 (last estimated June 2027)
2026-06-10
Trial status changed: Recruiting → Active, Not Recruiting
Trial Details
NCT Number NCT06029439
Lead Sponsor Neumora Therapeutics, Inc.
Conditions Major Depressive Disorder
Enrollment 904 participants
Start Date 2023-11-10
Primary Completion 2026-08-17 (estimated)
Study Completion 2026-08-17 (estimated)
Updated on ClinicalTrials.gov 2026-09-14